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Abstract Cells have stringent DNA repair pathways that
are specific for each different set of DNA lesions which is
accomplished through the integration of complex array of
proteins. However, BRCA-mutated breast cancer (BC) has
defective DNA repair mechanisms. This study aims to in-
vestigate differential expression of a large panel of DNA
repair markers to characterise DNA repair mechanisms in
BRCA-associated tumours compared to sporadic tumours in
an attempt to characterise these tumours in routine practice.
Immunohistochemistry and tissue microarray technology
were applied to a cohort of clinically annotated series of
sporadic (n = 1849), BRCA1-mutated (n = 48), and
BRCA2-mutated (n = 27) BC. The following DNA dam-
age response (DDR) markers are used; BRCA1, BRCA2,
RAD51, Ku70/Ku80, BARD, PARP1 (cleaved), PARP1
(non-cleaved), and P53 in addition to basal cytokeratins,
ER, PR, and HER2. A significant proportion of BRCA1
tumours were positive for PARP1 (non-cleaved), and
negative for BARD1 and RAD51 compared with sporadic
BC. BRCA2 tumours were significantly positive for PARP1
(non-cleaved) compared with sporadic tumours. RAD51
was significantly higher in BRCA1 compared with BRCA2
tumours (p = 0.005). When BRCA1/2 BCs were compared
to triple-negative (TN) sporadic tumours of the studied
DDR proteins, BARD1 (p \ 0.001), PARP1 (non-cleaved)
(p \ 0.001), and P53 (p = 0.002) remained significantly
different in BRCA1/2 tumours compared with TN BC.
DNA repair markers showed differential expression in
BRCA-mutated tumours, with a substantial degree of dis-
ruption of DNA repair pathways in sporadic BC especially
TN BC. DNA double-strand break (DSB) repair is assisted
by PARP1 expression in BRCA-mutated tumours, whereas
the loss of DSB repair via RAD51 is predominant in
BRCA1 rather than BRCA2 BC.
Keywords DNA repair  DNA damage response  BRCA-
mutated breast cancers
Introduction
DNA repair deficiencies are well-known risk factors for a
variety of cancers [1]. Cells have numerous DNA repair
pathways that are specific for each different set of lesions.
In each pathway, several proteins are involved that interact
with each other in order to guarantee the repair of the
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damage. When one of the mechanisms becomes inefficient,
often some others prosper, turning the DNA repair towards
another pathway. When even the alternate mechanism is
damaged, the consequent genetic instability leads to cell
death [2]. Traditional chemotherapy often employs DNA-
damaging agents whose success or failure depends on the
DNA repair capacity of the cells [3]. Knowing the damaged
pathway can help understand the interaction between the
different DNA repair systems and find candidate targets for
therapy through the use of the mechanism known as syn-
thetic lethality [4]. For instance, the selective inhibition of
PARP (Poly ADP-ribose polymerase, an enzyme involved
in base excision repair) leads to the persistence of DNA
lesions resulting in chromosomal instability, cell cycle ar-
rest, and subsequent apoptosis leading ultimately to kill
selectively the tumour cells [5].
BRCA1 and BRCA2 proteins have been implicated in
the repair of double-strand DNA breaks (DSB) to main-
tain genomic stability by homologous recombination
(HR) [6]. BRCA1 is important to recruit DNA repair
proteins to the sites of damage, while BRCA2 catalyses
the formation of RAD51 filaments on single-stranded
DNA at the damaged sites. The BRCA2 homologue Brh2
nucleates RAD51 filament formation at a dsDNA–ssDNA
junction [7]. In this study, the immunohistochemical
(IHC) expression of a panel of DNA damage repair in-
cluding BRCA1, BRCA2, RAD51, Ku70/Ku80, BARD,
PARP1 (cleaved), and PARP1 (non-cleaved) is assessed
in an invasive BC series including a test set of BRCA1/2
mutant cases and a control set of sporadic BC. This panel
of markers includes molecular markers essential for both
mechanisms of DNA DDR, namely HR and non-ho-
mologous end joining (NHEJ), and work in partnership
with BRCA1 and BRCA1 [8]. While PARP1 is involved
in base excision repair occurring in response to DNA
damage [9], BARD1 functions in association with
BRCA1 [10]. The RAD51 is a key component of DNA
damage repair by the error-free HR mechanism associ-
ated with the activation of DSB DNA repair and works
in association with BRCA1 and BRCA2 [11]. On the
other hand, Ku70/Ku80 is a heterodimer playing crucial
roles in the regulation of diverse cellular processes in-
cluding NHEJ, transcription regulation, and DNA repli-
cation [12].
The expression of this selected panel of DNA repair-
related proteins in selected tumours of BRCA1 and BRCA2
mutations is compared to sporadic BC, highlighting the
differences between hereditary and sporadic cancers with
the aim to recognise the specific profile expression pattern
in each population. The more insights into the specific
DNA repair mechanism in BRCA-mutated and sporadic
invasive BC, the more the opportunities of opening new
avenues for therapeutic strategies.
Materials and methods
Patient series
This retrospective study was performed on formalin-fixed
paraffin-embedded (FFPE) archival tumour tissues from
patients being treated at the Nottingham University
Hospitals NHS Trust. Representative tumour tissues were
prepared as tissue microarrays (TMA), which were subject
to IHC using a broad panel of markers of close relevance to
BC biology/classification in addition to markers of DNA
damage repair. This study was conducted using two inde-
pendent cohorts of patients, as follows:
BRCA tumours
A total of 75 tumour samples from 68 patients with con-
firmed germline mutations for BRCA1 or BRCA2, including
seven bilateral cancers, were available for inclusion in this
study. The BRCA-mutated tumours consisted of 44 BRCA1
mutations and 24 BRCA2 mutations. The average age of
patients at diagnosis was 42 years: 40 for BRCA1 carriers
and 45 for BRCA2 carriers. Fifteen patients had bilateral
cancer, eleven (11/44, 25 %) were BRCA1 carriers, and
four (6/24, 16.7 %) were BRCA2 carriers. Thirty-one pa-
tients (31/68, 45.6 %) had prophylactic mastectomy. Seven
patients (10.3 %) also had ovarian cancer; with 48/68
(70.6 %) patients underwent prophylactic oophorectomy.
The most common type of surgery was mastectomy (44
patients, 64.7 %), 22 of them were bilateral mastectomies.
For the remaining 24 patients (35.3 %), wide-local exci-
sion was performed.
The mean overall survival following surgical interven-
tion was 121.5 and 87.3 months in BRCA1 and BRCA2
patients, respectively, with a total of 11/44 (25 %) deaths
occurred in the former, and 8/24 (33.3 %) occurred in the
latter. Twelve patients (17.6 %) experienced a recurrence;
seven (15.9 %) were BRCA1 carriers and 5 (20.8 %)
BRCA2 carriers. Metastatic disease occurred in 19 patients
(27.9 %), 12 (27.3 %) in the BRCA1 and 7 (29.2 %) in the
BRCA2 population.
Sporadic tumours
The control population was based on a well-characterised
consecutive series of early-stage (TNM Stage I–III) pri-
mary operable invasive BC from patients (age B 70 years)
enrolled into the Nottingham Tenovus Primary Breast
Carcinoma Series presented at Nottingham City Hospital
between 1986 and 1998 (n = 1844). Patients’ clinical
history, tumour characteristics, and information on therapy
and outcomes are prospectively maintained. Outcome data
included survival status, survival time, cause of death and
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development, and time to local, regional recurrence or
distant metastasis (DM).
Tissue arrays and immunohistochemistry
Tumour samples were arrayed as previously described
[13]. Briefly, tissue cores with a diameter of 0.6 mm were
punched from the representative tumour regions of each
donor FFPE block. Cores were precisely arrayed into a
recipient paraffin block using a tissue microarrayer (TMA
Grand Master, 3DHistech Ltd).
Immunohistochemical staining was performed on 4 lm
sections using Novolink polymer detection system (Leica
Biosystems, RE7150-K). Supplementary Table 1 shows
the dilution, source and clone of antibodies used in this
study. Briefly, tissue slides were deparaffinised with xylene
and rehydrated through three changes of alcohol. Antigen
retrieval (except for EGFR and HER2) was performed in
citrate buffer (pH 6.0) for 20 min using a microwave oven.
Endogenous peroxidase activity was blocked by Peroxidase
Block for 5 min. Slides were washed with TBS (pH 7.6),
followed by the application of Protein Block for 5 min.
Following another TBS wash, primary antibody, optimally
diluted in Leica antibody diluent (RE7133), was applied
and incubated for 60 min. Slides were washed with TBS
followed by incubation with Post-Primary Block for
30 min followed by a TBS wash. Novolink polymer was
applied for 30 min. DAB working solution made up of 1:20
DAB chromogen in DAB substrate buffer was prepared
and applied for 5 min. Slides were counterstained with
Novolink haematoxylin for 6 min, dehydrated, and cover-
slipped. Negative (omission of the primary antibody) and
positive controls were included according to manufacturer
datasheet of each antibody.
Evaluation of immunohistochemical staining
The TMA slides were initially assessed by light micro-
scope assessment of staining quality and specificity. Slides
were then scanned into high-resolution digital images
(0.45 lm/pixel) using a NanoZoomer slide scanner (Ha-
mamtsu Photonics, Welwyn Garden City, UK) and ac-
cessed using a web-based interface (Distiller, SlidePath
Ltd, Dublin, Ireland). They were scored at 920 magnifi-
cation using a minimum of 2400 high-resolution screen
(91920 1080). Cases were scored without knowledge of
the BRCA status and patient outcome and were scored by
three people (DC, MA, and ARG).
Assessment of staining was based on a semi-quantitative
approach using a modified histochemical score (H-score)
taking the intensity of staining and the percentage of
stained cells into account [14]. For the intensity, a score
index of 0, 1, 2, and 3 corresponding to negative, weak,
moderate, and strong staining intensity was used, and the
percentage of positive cells at each intensity was estimated
subjectively. Cut-off points of the other biomarkers in-
cluded in this study were chosen as per previous publica-
tions [15, 16]. BC molecular subtypes were classified based
on their IHC expression profile for ER, PgR, HER2, CK5/
6, CK14, and EGFR into (1) luminal (ER? and/or PR?/
HER2-); (2) HER2? (HER2 positive); and (3) Triple-
negative (TN; ER-, PR-, HER2-) including basal (TN-
Basal, TN and positive for CK5/6, and/or EGFR and/or
CK14) and non-basal (TN-non-basal) (negative for all five
markers) [16].
Statistical analysis
Statistical analysis was performed using SPSS 17.0 statis-
tical software. Univariate and multivariate analyses were
performed by Chi squared and Log-rank tests. Kaplan and
Meier (1958) plots were used to visualise the survival
distribution of studied patients’ subgroups, with differences
in survival estimated using Log-rank tests. A p val-
ue \ 0.01 (two-tailed) was considered significant. This
study adheres to REporting recommendations for tumour
MARKer prognostic studies (REMARK) criteria [17].
Results
Clinico-pathological parameters between BRCA-
mutated and sporadic breast tumours
Supplementary Fig. 1 depicts representative examples of
IHC expression of DNA damage response markers in in-
vasive BC tissue cores. The histological parameters were
compared among the sporadic, BRCA1, and BRCA2 tu-
mours, which are summarised in Table 1. BRCA1 and
BRCA2 tumours were of significantly higher grade than the
sporadic tumours (p \ 0.001) where 90 % of BRCA1 tu-
mours were grade 3 compared with 47 % in the sporadic
series. The same applies to the components of histological
grade, where less tubule formation and more nuclear
pleomorphism were similarly significantly associated with
BRCA-mutated tumours. In addition, BRCA1 tumours had a
higher mitotic frequency than sporadic and BRCA2 tu-
mours (p \ 0.01). Medullary-like tumours were sig-
nificantly more frequent in BRCA1-mutated tumours
compared with sporadic tumours (p \ 0.001). There was
no significant difference between BRCA2 tumours and
sporadic cases in terms of histological type, but lobular
tumours were more common in BRCA2 tumours than in
BRCA1 tumours (p = 0.010). However, there were no
significant differences in tumour size, stage, or presence of
vascular invasion observed between the studied series.
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Biological characteristics between BRCA-mutated
and sporadic BC
A significantly higher proportion of BRCA1-mutated tumours
showed a lack of ER expression (83.0 %) compared with the
sporadic (22.3 %) and BRCA2 (14.8 %) tumours (p \ 0.001,
Table 2). PgR was similarly expressed to ER which was more
prevalent in the sporadic and BRCA2 tumours than the BRCA1
tumours. Nevertheless, there was no significant difference in
the expression of HER2 between the BRCA-mutated tumours
and sporadic cases. Triple-negative tumours were highly
represented in the BRCA1-mutated tumours (32/48, 67.4 %)
compared with both sporadic (16.1 %, p \ 0.001) and
BRCA2 tumours (7.4 %, p \ 0.001).
Likewise, positive basal cytokeratin (CK5/6 and CK14)
and EGFR expression was significantly more common in
BRCA1 tumours compared with sporadic or BRCA2 tumours.
Consequently, basal phenotype was significantly more fre-
quent in BRCA1 tumours (72.7 %) compared with sporadic
(24.1 %, p \ 0.001) and BRCA2 (24.0 %, p \ 0.001)
Table 1 Histopathological characteristics of the sporadic and BRCA-mutated breast cancer series and their statistical correlations
Parameter BRCA1 mutated
cancer (n = 48)
n (%)
BRCA2 mutated
cancer (n = 27)
n (%)
Sporadic
cancer (n = 1849)
n (%)
BRCA1
versus sporadic
p value
BRCA2
versus sporadic
p value
BRCA1
versus BRCA2
p value
Grade
1 1 (2.1) 0 344 (18.7) \0.001 0.001 NS
2 4 (8.3) 7 (24.0) 628 (34.1)
3 43 (89.6) 20 (74.1) 871 (47.1)
Tubule formation
1 0 0 116 (6.5) NS <0.001 NS
2 9 (19.1) 2 (7.4) 594 (33.2)
3 38 (80.9) 25 (92.6) 1077 (60.3)
Pleomorphism
1 1 (2.2) 1 (3.7) 47 (2.6) <0.001 <0.001 NS
2 2 (4.3) 2 (7.4) 728 (40.8)
3 43 (93.5) 24 (88.9) 1008 (56.5)
Mitotic frequency
1 1 (2.1) 5 (18.5) 682 (38.2) <0.001 NS 0.005
2 6 (12.8) 8 (29.6) 335 (18.7)
3 40 (85.1) 14 (51.9) 770 (43.1)
Tumour size
\2 cm 24 (50) 11 (40.7) 953 (51.7) NS NS NS
C2 cm 24 (50) 16 (59.3) 890 (48.3)
Histological type
Ductal 39 (81.2) 18 (66.7) 1485 (80.3) <0.001 NS 0.010
Lobular 1 (2.1) 7 (25.9) 206 (11.1)
Medullary-like 7 (14.6) 2 (7.4) 42 (2.3)
Other 1 (2.1) 0 116 (6.3)
Vascular invasion
No 29 (63) 20 (74.1) 1264 (68.7) NS NS NS
Yes 17 (37) 7 (25.9) 576 (31.2)
Stage
1 30 (65.2) 17 (63) 1166 (63.3) NS NS NS
2 15 (32.6) 8 (29.6) 524 (28.4)
3 1 (2.2) 2 (7.4) 153 (8.3)
Nottingham prognostic index
Good 3 (6.5) 6 (22.2) 614 (33.3) <0.001 NS NS
Moderate 34 (73.9) 15 (55.6) 943 (51.2)
Poor 9 (19.6) 6 (22.2) 286 (15.5)
p value in bold in these tables means statistically significant associations
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tumours. Additionally, TN-basal tumours were significantly
associated with BRCA1-mutated tumours compared with
sporadic or BRCA2 tumours (both p \ 0.001).
The proliferation marker Ki67 was highly expressed in
BRCA1 tumours (43/45, 95.6 %) compared with sporadic
BC (920/1453, 63.3 %, p \ 0.001). There was no differ-
ence between BRCA2 and BRCA1 tumours in terms of
Ki67 expression (21/26, 84.0 %).
There was no significant difference in any of the clinico-
pathological parameters between TN or TN-basal sporadic
and TN BRCA1-mutated BC (data not shown).
Expression of DNA repair markers in BRCA-mutated
BC
There was a significant difference in BRCA1 protein ex-
pression in both BRCA1- and BRCA2-mutated BC com-
pared with sporadic cases (Table 3). In pairwise
comparisons, BRCA1 protein showed significantly differ-
ent expression between all the studied series. In addition,
significant differences were observed between BRCA1/2-
mutated and sporadic tumours regarding BRCA2 protein
expression (p = 0.007, and p \ 0.001, respectively).
Table 2 Biological characteristics of sporadic and BRCA-mutated breast cancers and their statistical correlations
BRCA1 mutated
cancer
(n = 48) n (%)
BRCA2
mutated cancer
(n = 27) n (%)
Sporadic
cancer
(n = 1849) n (%)
BRCA1 versus
sporadic
p value
BRCA2
versus sporadic
p value
BRCA1
versus BRCA2
p value
ER
Negative 39 (83.0) 4 (14.8) 413 (22.3) <0.001 NS <0.001
Positive 8 (17.0) 23 (85.2) 1436 (77.7)
PgR
Negative 34 (73.9) 6 (24.0) 703 (39.5) <0.001 NS <0.001
Positive 12 (26.1) 19 (76.0) 1078 (60.5)
HER2
Negative 45 (95.7) 26 (96.3) 1551 (87.2) NS NS NS
Positive 2 (4.3) 1 (3.7) 228 (12.8)
CK5/6
Negative 17 (38.6) 19 (76.0) 1478 (82.8) <0.001 NS 0.003
Positive 27 (61.4) 6 (24.0) 307 (16.6)
CK14
Negative 29 (64.4) 24 (100) 1501 (89.0) <0.001 NS 0.002
Positive 16 (35.6) 0 185 (11.0)
EGFR
Negative 28 (62.2) 23 (88.5) 1403 (79.7) 0.004 NS NS
Positive 17 (37.8) 3 (11.5) 357 (20.3)
TN
No 15 (32.6) 25 (92.6) 1552 (83.9) <0.001 NS <0.001
Yes 31 (67.4) 2 (7.4) 297 (16.1)
Basal phenotype
No 12 (27.3) 19 (76.0) 1353 (75.2) <0.001 NS <0.001
Yes 32 (72.7) 6 (24.0) 446 (24.1)
TN and basal
No 20 (45.5) 26 (96.3) 1633 (88.5) <0.001 NS <0.001
Yes 24 (54.5) 1 (3.7) 212 (11.5)
Ki67
Negative 2 (4.4) 4 (16.0) 533 (36.7) <0.001 NS NS
Positive 43 (95.6) 21 (84.0) 920 (63.3)
p value in bold in these tables means statistically significant associations
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PARP1 (non-cleaved) expression was significantly higher
in BRCA1 (93.5 %) and BRCA2 (88 %) tumours compared
with sporadic cases (48.8 %; p \ 0.001). However, P53
expression was not significantly expressed between any of
the studied series (p [ 0.05).
Significantly lower RAD51 expression was observed in
BRCA1-mutated tumours (8/48, 19.5 %) compared with
BRCA2 (11/24, 45.8 %; p = 0.024) and sporadic breast
cancers (429/896, 47.9 %, p \ 0.001). Moreover, BARD1
was significantly less expressed in BRCA1/2-mutated tu-
mours than sporadic tumours (21/45; 46.7 %, 18/24; 75 %,
and 1113/1119; 99.5 %, respectively, p \ 0.001), and
BRCA1- than BRCA2-mutated tumours (p = 0.024),
Table 3.
However, PARP1 (cleaved) and Ku70/Ku80 were
similarly highly expressed in the majority of BRCA-mu-
tated and sporadic BC (p [ 0.05). Furthermore, P53
showed comparably low frequencies of expression in all
the studied series with differences not reaching statistical
significance (p [ 0.05).
The expression of DNA repair markers in sporadic TN
and BRCA1/2-mutated BC showed significant differences
in the expression of BARD1, PARP1 (non-cleaved), and
P53, and BRCA2 expression in BRCA2-mutated BC only
(Supplementary Table 2). In this respect, the vast majority
of TN BRCA1-mutated tumours were PARP1 positive
compared to TN sporadic BC (93.5, and 52.7 % respec-
tively, p \ 0.001). On the contrary, 21/45 cases (46.7 %)
of the BRCA1-mutated tumours and 18/27 (75 %) of
BRCA2-mutated tumours were BARD1 positive compared
to 297/297 (100 %) of the TN sporadic tumours
(p \ 0.001). In line with BARD1 expression, P53 was
significantly more frequent in TN sporadic tumours than
BRCA1- and BRCA2-mutated tumours (57 and 22.7 and
17.4 %, respectively, p = 0.002). However, none of the
remaining studied DNA repair markers were significantly
different between TN sporadic and BRCA1/2-mutated tu-
mours (p [ 0.05, Supplementary Table 2). To further
scrutinise these associations, TN BRCA1 mutant cases were
identified (n = 31 cases) and compared to TN sporadic BC
regarding the expression of the studied DNA repair
markers panel. Interestingly, the same significantly differ-
ent markers (BARD1, P53, and PARP1 non-cleaved)
maintained their significant expression between TN
Table 3 DNA repair markers in sporadic and BRCA-mutated breast cancers
Parameter BRCA1 mutated
(n = 48) n (%)
BRCA2 mutated
(n = 27) n (%)
Sporadic cancer
(n = 1849) n (%)
BRCA1 versus
sporadic p value
BRCA2 versus
sporadic p value
BRCA1 versus
BRCA2 p value
BARD1 (cyto)
Negative 24 (53.3) 6 (25.0) 6 (0.5) <0.001 <0.001 0.024
Positive 21 (46.7) 18 (75.0) 1113 (99.5)
BRCA1 (nuclear)
Negative/Low 32 (76.2) 22 (95.7) 626 (43.8) <0.001 <0.001 0.045
Positive 10 (23.8) 1 (4.3) 804 (56.2)
BRCA2 (nuclear)
Negative 28 (80.0) 15 (68.2) 1014 (92.4) 0.007 <0.001 NS
Positive 7 (20.0) 7 (31.8) 83 (7.6)
Ku70/Ku80
Negative 2 (4.4) 0 102 (10.2) NS NS NS
Positive 43 (95.6) 25 (100) 895 (89.8)
P53
Negative 33 (73.3) 19 (82.6) 1278 (72.2) NS NS NS
Positive 12 (26.7) 4 (17.4) 492 (27.8)
PARP1 (non-cleaved)
Negative 3 (6.5) 3 (11.5) 526 (51.2) <0.001 <0.001 NS
Positive 43 (93.5) 23 (88.5) 501 (48.8)
PARP1 (cleaved)
Negative 1 (2.6) 0 28 (2.3) NS NS NS
Positive 43 (97.7) 25 (100) 1187 (97.7)
RAD51 nuclear
Negative 33 (80.5) 13 (54.2) 467 (52.1) <0.001 NS 0.024
Positive 8 (19.5) 11 (45.8) 429 (47.9)
p value in bold in these tables means statistically significant associations
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sporadic BC and TN BRCA1 mutant BC, Supplementary
Table 3.
BRCA mutations and patient outcome
There was no significant difference in overall survival
between BRCA1 and BRCA2 tumours or between BRCA1
versus sporadic or BRCA2 versus sporadic tumours (data
not shown). Likewise, there was no significant difference in
patient survival between BRCA1 or BRCA2 tumours and
sporadic tumours taking into consideration DNA repair
markers (data not shown).
Discussion
Etiologically, BC is classified into sporadic and familial
forms, with the latter forming up to 5–10 % of invasive
BC. BRCA-related familial BC is caused by germline
mutations either in the BRCA1 or BRCA2 genes and is
associated with an increased risk of developing breast and
other cancers [18]. However, in sporadic BC, mutational
inactivation of BRCA1/2 is a rare occurrence, as inactiva-
tion requires both gene alleles to be mutant or totally
deleted. However, non-mutational functional suppression
of BRCA1/2 could result from various mechanisms, such as
hypermethylation of the BRCA1 promoter or silencing of
BRCA2 by other proteins [19, 20]. Moreover, BRCA genes
function in a highly coordinated manner in concert with a
complex array of genes to carry out high-fidelity repair of
DNA damages. However, the expression of these DNA
damage repair genes in clinical BC samples and their as-
sociations with clinico-pathological parameters have so far
yielded controversial findings.
We have used two well-characterised cohorts of inva-
sive BC with updated comprehensive biomarkers, includ-
ing DNA damage response proteins, and outcome data to
assess the pathobiological and clinical features of tumours
harbouring BRCA1 and BRCA2 mutations compared to
sporadic BC.
Regarding their clinico-pathological criteria, BRCA1/2
tumours when compared with sporadic tumours were sig-
nificantly poorly differentiated/higher grade with less
tubule formation and more nuclear pleomorphism. BRCA1
tumours had a higher mitotic frequency than sporadic and
BRCA2 tumours. The vast majority of BRCA1 tumours
showed higher proliferative index as assessed by Ki67LI
compared to sporadic cancers. However, BRCA2 and
BRCA1 tumours were neither different from each other
regarding their Ki67LI, nor the BRCA2 tumours were
significantly different from the sporadic tumours. These
findings go in line with previous reports [21, 22]. More-
over, medullary-like tumours were significantly more
frequent in BRCA1-mutated tumours. Although the latter
has long been recognised [23], it underscores the potential
significance of histologic observations, medullary histo-
logic criteria reported by pathologists in patients’ clinical
care [24]. Nevertheless, BRCA2 tumours were not sig-
nificantly different from sporadic cases in terms of histo-
logical type. However, lobular tumours were more
common in BRCA2 tumours than in BRCA1 tumours.
The majority of BRCA1-mutated tumours were ER
negative compared to sporadic and BRCA2 tumours with
similar expression pattern observed for PgR. Moreover, TN
tumours were significantly more represented in the
BRCA1-mutated tumours compared with both sporadic and
BRCA2 tumours. Furthermore, BRCA1 tumours displayed
significantly higher proportions of basal BC than sporadic
and BRCA2 tumours as evidenced by significant session of
the basal markers CK5/6, CK14, and EGFR. Accordingly,
TN-basal tumours were significantly associated with
BRCA1-mutated tumours compared with sporadic or
BRCA2 tumours. These findings are in agreement with our
previous report [16] and those of gene microarray studies
[25]. Additionally, BRCA1-mutated BCs were not sig-
nificantly different from TN-non-basal or TN-basal spo-
radic tumours in any of the known clinico-pathological
parameters. These findings describing the clinico-patho-
logical associations of BRCA1/2 tumours are in agreement
with those previously described [26]. BRCA2 tumours ap-
pear to show a phenotype between sporadic and BRCA1-
associated BC. In other words, the IHC profile of BRCA1-
mutated BC is distinctively different from sporadic BC
more than BRCA2-mutated tumours.
Regarding the biomarkers’ profile of DNA damage re-
pair markers in the studied series, there was, as expected, a
significantly reduced expression of BRCA1 and BRCA2
proteins in both BRCA1- and BRCA2-mutated BC com-
pared with sporadic cases. Moreover, BRCA1 protein was
significantly more expressed in BRCA1-mutated tumours
compared to BRCA2-mutated tumours. However, BRCA2
protein did not show significant difference in expression
between BRCA1- versus BRCA2-mutated tumours.
PARP1 is a known key facilitator of DNA repair and is
implicated in pathways of carcinogenesis. It is a 113 kDa
nuclear enzyme which is cleaved into two fragments (89
and 24 kDa) during apoptotic cell death [27]. In this study,
only non-cleaved PARP1 showed significantly different
expression between the studied series, while the cleaved
PARP1, whose levels are known to be increased in apop-
tosis, did not show any significantly different expression.
The vast majority of BRCA1 (93.5 %) and BRCA2
(88.5 %) tumours were significantly positive for PARP1
(non-cleaved) expression compared to only half of the
sporadic cases. With BRCA1 or BRCA2 loss of function
due to mutations, cells become deficient in DNA DSB
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repair. This in turn activates PARPs whose catalytic ac-
tivity is immediately stimulated by DNA breaks. It is not,
therefore, surprising for the BRCA1/2 cases in our series
overexpressing PARP1 (non-cleaved), which appears to be
the reactive response of cells when DNA damage repair by
BRCA gene is defective, and has been recently reported in
BRCA1 mutant breast cancer cell lines and BRCA1-mutated
BC cases [28]. Our results are in line with previous studies
[27, 29, 30]. The relatively high percentages of sporadic
BC positive for PARP1 (non-cleaved) prompted some au-
thorities to suggest the potential therapeutic benefits of
PARP1 inhibitors not only in familial BRCA-mutated BC
but in sporadic cancers as well [31]. On the other hand,
PARP1 cleaved isoform which has been regarded as a
useful hallmark of activated cellular apoptotic machinery
[9] did not show any significantly different expression
between the studied series, with the vast majority of cases
in all series showing positive expression. In our recent
report, cleaved PARP1 was found to be highly significantly
associated with other DNA repair proteins including
RAD51, CHK1, CHK2, and others [32]. This overexpres-
sion of cleaved PARP1 in our series could point out to its
roles in DNA repair, in addition to the recently reported
functions of transcriptional regulation of other molecular
regulators [33].
BARD1 gene encodes a protein that forms heterodimers
with BRCA1 N-terminal region. This stable BARD1/
BRCA1 complex is crucial for BRCA1 tumour suppression
and coordinates a diverse range of cellular pathways such
as DNA repair, transcriptional regulation to maintain ge-
nomic stability, and others [34]. BARD1 in this study was
significantly down-regulated in the BRCA-mutated series
compared to sporadic BC series. Nearly all cases of the
latter showed positive expression, while three-quarters and
up to half of the BRCA1-mutated cases and BRCA2-mu-
tated cases were BARD1 positive, respectively. The con-
comitant reduction of BARD1 expression in BRCA1
mutant cases underscores that the participation of BARD1
may be required for proper functioning of BRCA1-medi-
ated tumour suppressor activity aiming ultimately to
maintain chromosome integrity through HR mechanism
[10].
RAD51 is a key component of DNA damage repair by
HR mechanism associated with the activation of DSB DNA
repair. It binds to single- and double-stranded DNA giving
rise to a RAD51 nucleoprotein filament, which is essential
for strand-pairing reactions during DNA recombination
[11, 35]. Both BRCA1 and BRCA2 co-localise with
RAD51 at sites of DNA damage and activate HR repair of
DSB mediated by RAD51 [36]. In this study, significantly
lower RAD51 expression was observed in BRCA1-mutated
tumours relative to BRCA2 and sporadic BC. Thus, BRCA1
dysfunction caused by inactivating mutations appears to
deregulate nuclear RAD51 levels. Similar findings were
reported in BRCA1 mutant ovarian cancer cell lines which
displayed lowest levels of BRCA1 and RAD51 [37].
Moreover, lower RAD51 nuclear expression was observed
in prostatic carcinomas associated with BRCA1/2 muta-
tions than sporadic cancers [38]. Reduced nuclear expres-
sion of RAD51 has been reported concomitantly with
reduced nuclear expression of BRCA1 and BRCA2 protein
expression in early invasive BC [39]. However, in our
study, BRCA2 mutated tumours were not significantly
different from the sporadic BC. Although BRCA2 is
needed for RAD51 nuclear localisation [40], other
BRCA2-independent mechanisms involving other proteins,
for instance RAD51C, have also been proposed [6].
The tumour suppressor P53 showed closely comparable
low expression in BRCA1/2 and sporadic tumours with no
significant differences between the studied series. In other
words, up to three-quarters to around four-fifths of the
studied series have negative P53 expression. These results
of low P53 expression in BRCA mutant BC are in agree-
ment with the findings reported by Zakhartseva and co-
authors in invasive BC [41]. However, they are contra-
dicting other studies describing the collaborative syner-
gistic functionality of P53 mutations for the tumourigenic
influence of BRCA2 loss [42] and BRCA1 loss [43]. P53
inactivation through protein-truncating mutations, rather
than hotspot mutations, has been reported to be one of the
mechanisms which accompany BRCA loss, which could
not be always detected by IHC expression of P53 protein.
This could, at least in part, explain the low levels of P53
expression, and hence inactivation, in our BRCA mutant
series. Accordingly, this has prompted some authorities to
report on the inherent weakness of immunohistochemical
detection of TP53 inactivation that could lead to misdiag-
nosis in significant proportions of BRCA1 mutant tumours
[43].
Ku70/Ku80 is a heterodimer known to play crucial roles
in regulating diverse cellular processes including NHEJ,
transcription regulation, and DNA replication [12]. In this
study, Ku70/Ku80 was similarly highly expressed in the
studied series, where all BRCA2-mutated and 95.6 % of
BRCA1-mutated BC cases showed positive expression.
These results are in agreement with our recent report using
IHC on invasive BC cases and reverse phase protein array
on cell lysates from BRCA1-deficient BC cell lines [44].
These figures might indicate over-activation of non-ho-
mologous end joining (NHEJ) known to be mediated by
Ku70/Ku80 as a back-up alternative mechanism for DNA
DSB repair in cases when BRCA1/2 are mutated with al-
tered HR DNA repair pathway.
Currently, it is widely accepted that the biologic pro-
cesses carried out by BRCA1 are disrupted by numerous
mechanisms in sporadic cancers especially the TN and
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basal-like BC. Therefore, we have restricted the analysis to
compare TN sporadic BC with BRCA1/2-mutated tumours.
Expectedly, there were no statistically significant differ-
ences between the TN and basal-like phenotypes regarding
any of the clinico-pathological parameters. Interestingly,
both had large proportions of large tumour size and the vast
majority were high-grade and moderate/poor NPI. Of the
DNA repair markers studied, PARP1 (non-cleaved) showed
significantly more positivity in BRCA1-mutated tumours.
Although more than 90 % of the latter showed PARP1
overexpression, up to 53 % of the TN sporadic tumours
were also PARP1 (non-cleaved) positive. Moreover, both
phenotypes showed more BRCA1/2-negative, RAD51-
negative, and Ku70/Ku80-positive expression. The same
pattern of association were maintained when the analyses
were further restricted between TN BRCA1-mutated cases
and TN sporadic BC. In other terms, in both phenotypes, the
HR protein RAD51 showed reduced expression, while the
NHEJ protein Ku70/Ku80 was similarly overexpressed.
Furthermore, BARD1 and the tumour suppressor P53
showed significantly lower expression in BRCA1/2 mutant
and TN BRCA1/2 mutant tumours compared with TN spo-
radic BC cases. Collectively, these findings refer to the
properties that define ‘BRCAness’ of sporadic BC. These
are the traits that some sporadic cancers could share with
those occurring in either BRCA1 or BRCA2 mutation car-
riers [45, 46]. These shared properties between the TN
sporadic and familial cancers might have important impli-
cations in clinical management of these cancers. This
highlights the potential therapeutic benefit of PARP1 in-
hibitors, based on the hypothesis of synthetic lethality, in TN
sporadic as well as BRCA1-mutated BC [47].
In conclusion, the results of this study demonstrate, at a
translational level, the complexity of DNA repair
mechanisms in BRCA-mutated tumours and the presence of
a degree of disruption of these pathways especially in TN
BC. Moreover, our results support the hypothesis that
DSBs are repaired by one or more alternative pathways and
they are not independent of each other as evidenced by the
reciprocal relationship between markers of HR and NHEJ
of DNA DSB. Furthermore, DSB DNA repair is assisted by
PARP1 expression in BRCA-mutated tumours, whereas the
loss of DSB repair via RAD51 is predominant in BRCA1
rather than BRCA2 BC.
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